Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

D. Van Der Heijde, A. Deodhar, O. FitzGerald

Research output: Contribution to journalComment/debate

4 Scopus citations

Abstract

van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

Original languageEnglish (US)
Article number000582
JournalRMD open
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)'. Together they form a unique fingerprint.

  • Cite this